EBMT 2023 | The benefit of CAR-T therapy over autoSCT in 3L DLCBL & the promise of bispecifics in this setting
In this video, Marjolein van der Poel, MD, PhD, Maastricht University Medical Center, Maastricht, Netherlands, comments on the superiority of CAR-T therapy over autologous transplantation in patients with diffuse large B-cell lymphoma (DLBCL) in the third-line setting. Dr van der Poel comments on the efficacy of axicabtagene ciloleucel (axi-cel) and lisocabtagene maraleucel (liso-cel) and briefly discusses the ZUMA-7 trial (NCT03391466). Finally, she explains that encouraging data suggest that bispecific antibodies could be a promising alternative for patients who relapse after second-line therapy. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Takeda, Kite/Gilead: Honoraria
